Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam®10%) in patients with immune thrombocytopenia

Redimune® NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions

(2010) D. Piguet et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS)

(2009) Rienk Tamminga et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production

(2009) Diane Nugent et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

(2009) T. Robak et al.   Hematology

Clinical efficacy and safety of Flebogammadif®, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura

(2009) A. Julia et al.   TRANSFUSION MEDICINE

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD